Esperion Therapeutics Stock Forecast, Price & News

-0.02 (-0.07 %)
(As of 04/16/2021 12:00 AM ET)
Today's Range
Now: $27.02
50-Day Range
MA: $28.35
52-Week Range
Now: $27.02
Volume315,911 shs
Average Volume773,991 shs
Market Capitalization$755.02 million
P/E RatioN/A
Dividend YieldN/A
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Esperion Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ESPR
Year FoundedN/A



Sales & Book Value

Annual Sales$148.36 million
Book Value$0.73 per share


Net Income$-97,170,000.00


Market Cap$755.02 million
Next Earnings Date5/4/2021 (Confirmed)


Esperion Therapeutics (NASDAQ:ESPR) Shares Gap Down to $27.72
March 30, 2021 |
News for Esperion Therapeutics Inc
March 18, 2021 |
Is Esperion Therapeutics (ESPR) a Smart Long-term Buy?
February 26, 2021 |
Recap: Esperion Therapeutics Q4 Earnings
February 23, 2021 |
Is Esperion Therapeutics (ESPR) Stock a Buy For 2021?
February 3, 2021 |
Esperion Therapeutics: The Good, Bad and Ugly
February 3, 2021 |
See More Headlines


Overall MarketRank

1.19 out of 5 stars

Medical Sector

927th out of 2,025 stocks

Pharmaceutical Preparations Industry

438th out of 772 stocks

Analyst Opinion: 3.2Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
-0.02 (-0.07 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ESPR News and Ratings via Email

Sign-up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions

Is Esperion Therapeutics a buy right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 2 sell ratings, 4 hold ratings, 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Esperion Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESPR, but not buy additional shares or sell existing shares.
View analyst ratings for Esperion Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Esperion Therapeutics?

Wall Street analysts have given Esperion Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Esperion Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Esperion Therapeutics' next earnings date?

Esperion Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Esperion Therapeutics

How can I listen to Esperion Therapeutics' earnings call?

Esperion Therapeutics will be holding an earnings conference call on Tuesday, May 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) released its earnings results on Monday, February, 22nd. The biopharmaceutical company reported ($3.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.76) by $0.13. The biopharmaceutical company earned $9.64 million during the quarter, compared to analyst estimates of $12.52 million. Esperion Therapeutics had a negative net margin of 46.15% and a negative trailing twelve-month return on equity of 629.88%. Esperion Therapeutics's quarterly revenue was up 881.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($2.26) earnings per share.
View Esperion Therapeutics' earnings history

How has Esperion Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Esperion Therapeutics' stock was trading at $42.93 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ESPR stock has decreased by 37.1% and is now trading at $27.02.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ESPR?

10 equities research analysts have issued 1 year price objectives for Esperion Therapeutics' shares. Their forecasts range from $24.00 to $134.00. On average, they anticipate Esperion Therapeutics' stock price to reach $50.60 in the next year. This suggests a possible upside of 87.3% from the stock's current price.
View analysts' price targets for Esperion Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Esperion Therapeutics' key executives?

Esperion Therapeutics' management team includes the following people:
  • Mr. Timothy M. Mayleben M.B.A., Pres, CEO & Director (Age 60, Pay $1.08M)
  • Mr. Richard B. Bartram, CFO & Corp. Sec. (Age 39, Pay $485.5k)
  • Mr. Sheldon L. Koenig, Chief Operating Officer (Age 55)
  • Dr. Kenneth J. Fiorelli, Chief Technical Operations Officer
  • Mr. Benjamin Church, Head of Corp. Communications & Investor Relations
  • Mr. Keith F. Lenden, VP of Corp. Devel. & Strategy (Age 48)
  • Renee Marotta, Head of Marketing
  • Ms. Ashley Hall, Chief Devel. Officer (Age 49)
  • Ms. April Seiler, Sr. Director of Project Management
  • Roberta Peterson, Sr. Director of National Accounts

What is Tim Mayleben's approval rating as Esperion Therapeutics' CEO?

20 employees have rated Esperion Therapeutics CEO Tim Mayleben on Tim Mayleben has an approval rating of 80% among Esperion Therapeutics' employees.

Who are some of Esperion Therapeutics' key competitors?

What other stocks do shareholders of Esperion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include (ALDW) (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), The Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn).

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

Who are Esperion Therapeutics' major shareholders?

Esperion Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Pacer Advisors Inc. (0.01%). Company insiders that own Esperion Therapeutics stock include Target N V Biotech and Timothy M Mayleben.
View institutional ownership trends for Esperion Therapeutics

Which major investors are selling Esperion Therapeutics stock?

ESPR stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc..
View insider buying and selling activity for Esperion Therapeutics
or view top insider-selling stocks.

How do I buy shares of Esperion Therapeutics?

Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Esperion Therapeutics' stock price today?

One share of ESPR stock can currently be purchased for approximately $27.02.

How much money does Esperion Therapeutics make?

Esperion Therapeutics has a market capitalization of $755.02 million and generates $148.36 million in revenue each year. The biopharmaceutical company earns $-97,170,000.00 in net income (profit) each year or ($3.59) on an earnings per share basis.

How many employees does Esperion Therapeutics have?

Esperion Therapeutics employs 479 workers across the globe.

What is Esperion Therapeutics' official website?

The official website for Esperion Therapeutics is

Where are Esperion Therapeutics' headquarters?

Esperion Therapeutics is headquartered at 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108.

How can I contact Esperion Therapeutics?

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected]

This page was last updated on 4/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.